Acquire Develop Out-License

Our Expertise

A proven track record in search and evaluation, acquisition of new assets and out-licence of developed medicines

Meet Our Team

World renowned leadership and experience

  • Executive Team
  • Board of Directors

Dr Rajan Jethwa

Chief Executive Officer & Founder

Rajan has 15 years’ experience at the frontier of the life sciences industry as an internationally experienced executive and investment professional. Before founding Ellipses Pharma alongside Sir Chris Evans, he built and led a number of successful venture capital-backed businesses across the sector. Rajan is a member of the Royal College of Surgeons of England and graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. Rajan founded The Cancer Awareness Trust alongside Sir Chris Evans which is a unique digital platform providing essential guidance for living with cancer and throughout treatment.

David Cook

Chief Financial Officer

David has extensive experience of financial and general business management in the life sciences sector, financing businesses and managing investor relations. He is also Non-Executive Chairman of AIM listed Alliance Pharma plc. Previously he was chief financial officer and chief business officer of Biotie Therapies Corp and held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating from the University of Oxford with a degree in Chemistry.

James Sandy

Chief Development Officer

James has over 35 year deep expertise of all the phases of drug development from a career in the pharmaceutical and biotechnology industry. Previously James was Chief Development Officer at Immunocore and Head of Development Operations Oncology, Europe with Pfizer. James holds a MPhil in Statistics and Operational Research from Imperial College London.

Jon Maxmin

Director of Operations

As a corporate lawyer, Jon leads all elements of legal and IP across the company including overseeing the Ellipses IP strategies and patent portfolios and all in-licensing activities. Prior to Ellipses, Jon had wide experience across the healthcare and pharmaceutical sectors as a Partner and head of the Healthcare franchise at Skillcapital. He previously worked as a solicitor in the private equity teams at Allen & Overy and Weil, Gotshal & Manges. Jon holds a MA, Social and Political Sciences from Cambridge University, a postgraduate degree from the Cambridge Judge Business School and two postgraduate legal qualifications.

Professor Sir Christopher Evans OBE

Chairman & Founder

Sir Chris has launched, financed and supported more than 50 scientific companies, 20 of which have been listed on stock markets worldwide, including notable companies such as Chiroscience, Celsis, BioVex, ReNeuron, and Vectura. Sir Chris is a pioneer in the life sciences industry, having discovered and developed more than 20 innovative products for diseases such as cancer, arthritis, obesity and Parkinson’s disease. Appointed OBE in 1995 for services to medical bioscience, he was then knighted in 2001 for services to bioscience and enterprise. Sir Chris has advised governments in the UK and internationally on science over the last 35 years and founded a number of charitable ventures.

Waleed Al Mokarrab

Non-Executive

Waleed is the Deputy Group CEO for Mubadala Investment Company, responsible for strategic oversight of Mubadala’s broad investment portfolio and special projects. He holds directorships throughout the Middle East including chairman of the Cleveland Clinic, board member of Abu Dhabi Global Market, Emirates Investment Authority and First Abu Dhabi Bank.

Professor Maha Taysir Barakat OBE

Non-Executive Director

Professor Maha is a Senior Advisor at Mubadala and research director at the Imperial College London Diabetes Centre in Abu Dhabi, which she co-founded. She is former Director General of the Health Authority Abu Dhabi, chairs the RBM Partnership to End Malaria and is a member of the board of the Global Institute for Disease Elimination in Abu Dhabi. She was appointed OBE in 2010 and given the Imperial College Medal in 2013.

Dr Fahad Khater

Non-Executive Director

Dr Fahad is a physician and owner of Egypt's largest integrated healthcare system, responsible for eleven fully developed healthcare facilities, offering 900 beds and integrating labs, pharmacy, rehabilitation and long term care services.

Dr Rajan Jethwa

Chief Executive Officer & Founder

Rajan has 15 years’ experience at the frontier of the life sciences industry as an internationally experienced executive and investment professional. Before founding Ellipses Pharma alongside Sir Chris Evans, he built and led a number of successful venture capital-backed businesses across the sector. Rajan is a member of the Royal College of Surgeons of England and graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. Rajan founded The Cancer Awareness Trust alongside Sir Chris Evans which is a unique digital platform providing essential guidance for living with cancer and throughout treatment.

David Cook

Chief Financial Officer

David has extensive experience of financial and general business management in the life sciences sector, financing businesses and managing investor relations. He is also Non-Executive Chairman of AIM listed Alliance Pharma plc. Previously he was chief financial officer and chief business officer of Biotie Therapies Corp and held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating from the University of Oxford with a degree in Chemistry.

Our Scientific Affairs Group

Our Scientific Affairs Group is the largest oncology-focused network of key opinion leaders providing high-quality, independent and unbiased expertise

These leaders come either from the forefront of academic research or clinical practise, and often have a background in advising pharmaceutical drug development.

This global group of high-quality cancer practitioners is underpinned by a permanent core group of leading scientists, which complements the world-class and highly experienced Ellipses team.

Partners

Patient benefit through collaboration and partnership

Ellipses Pharma is committed to pursuing a collaborative approach to advancing cancer treatments. We build relationships with leading research institutions, charitable bodies, commercial pharma, biotech companies and outsourced development providers around the world

Our intention is to grow our strategic alliances around the world

Learn more about our proposition

Our proposition